Back to Search Start Over

Overcoming Doxorubicin Resistance with Lipid–Polymer Hybrid Nanoparticles Photoreleasing Nitric Oxide

Authors :
Claudia Conte
Salvatore Sortino
Chiara Riganti
Aurore Fraix
Elena Gazzano
Fabiana Quaglia
Fraix, A.
Conte, C.
Gazzano, E.
Riganti, C.
Quaglia, F.
Sortino, S.
Source :
Molecular Pharmaceutics. 17:2135-2144
Publication Year :
2020
Publisher :
American Chemical Society (ACS), 2020.

Abstract

We report on tailored lipid-polymer hybrid nanoparticles (NPs) delivering nitric oxide (NO) under the control of visible light as a tool for overcoming doxorubicin (DOX) resistance. The NPs consist of a polymeric core and a coating. They are appropriately designed to entrap DOX in the poly(lactide-co-glycolide) core and a NO photodonor (NOPD) in the phospholipid shell to avoid their mutual interaction both in the ground and excited states. The characteristic red fluorescence of DOX, useful for its tracking in cells, is well preserved upon incorporation within the NPs, even in the copresence of NOPD. The NP scaffold enhances the NO photoreleasing efficiency of the entrapped NOPD when compared with that of the free compound, and the copresence of DOX does not significantly affect such enhanced photochemical performance. Besides, the delivery of DOX and NOPD from NPs is also not mutually influenced. Experiments carried out in M14 DOX-resistant melanoma cells demonstrate that NO release from the multicargo NPs can be finely regulated by excitation with visible light, at a concentration level below the cytotoxic doses but sufficient enough to inhibit the efflux transporters mostly responsible for DOX cellular extrusion. This results in increased cellular retention of DOX with consequent enhancement of its antitumor activity. This approach, in principle, is not dependent on the type of chemotherapeutic used and may pave the way for new treatment modalities based on the photoregulated release of NO to overcome the multidrug resistance phenomenon and improve cancer chemotherapies.

Details

ISSN :
15438392 and 15438384
Volume :
17
Database :
OpenAIRE
Journal :
Molecular Pharmaceutics
Accession number :
edsair.doi.dedup.....4f43b33a1a5742e0cb6166c05a487579